The Potential Role and Effective Components of Sanyeqing as the Potential Therapeutic Candidates for IBD and CRC

Abstract

Inflammatory bowel disease (IBD) is a family of chronic inflammatory diseases such as Crohn's disease (CD) and ulcerative colitis (UC). Among the serious malignancies that can arise from IBD, colorectal cancer is particularly prevalent. Individuals suffering from both IBD and CRC often endure similar symptoms, which include diarrhea, rectal bleeding, abdominal discomfort, weight decline, and profound exhaustion. Sanyeqing is a traditional herbaceous medicinal plant with anti-tumor, anti-inflammatory, analgesic, heat-clearing, detoxifying, and liver-protecting effects. Here, we summarize the possible molecular mechanisms of IBD and CRC, and summarize the potential role of Sanyeqing in clinical therapy for IBD and CRC. Investigating the etiology of enteritis and intestinal cancer, as well as exploring Sanyeqing's potential as a preventive and therapeutic agent, is of paramount importance in the battle against these diseases.

Keywords: anti-inflammatory; anti-tumor; colorectal cancer; inflammatory bowel disease; sanyeqing.

Figure 1

Sanyeqing is shown. The aboveground part and the blocky root.

Figure 2

The active components of SYQ include flavonoids, polysaccharides, phenolic acids and other compounds. The biological effects of SYQ include anti-inflammatory effects, anti-tumor effects and antioxidant effects.